FibroGen Inc (FGEN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:FibroGen Inc (FGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9801
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
FibroGen Inc (FibroGen) is a biotechnology company that discovers, develops and commercializes new therapeutics. The company’s pipeline product portfolio includes FG-4592, an oral small molecule inhibitor of HIF prolyl hydroxylases that is used for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody developed to treat duchenne muscular dystrophy, idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. Its roxadustat is supported by extensive clinical data demonstrating correction and maintenance of hemoglobin levels in multiple subpopulations of CKD anemia patients. The company conducts research and development in the fields of connective tissue growth factor and hypoxia-inducible factor. FibroGen is headquartered in San Francisco, California, the US.

FibroGen Inc (FGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FibroGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
FibroGen Inc, Medical Devices Deals, 2012 to YTD 2018 9
FibroGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
FibroGen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 11
Equity Offering 12
FibroGen Raises USD374.9 Million in Public Offering of Shares 12
FibroGen Raises USD120 Million in Public Offering of Shares 13
FibroGen Raises USD168 Million in IPO of Shares 15
FibroGen to Raise USD20 Million in Private Placement of Shares 17
FibroGen Inc – Key Competitors 19
FibroGen Inc – Key Employees 20
FibroGen Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 07, 2018: FibroGen reports second quarter 2018 financial results 22
May 09, 2018: FibroGen Reports First Quarter 2018 Financial Results 23
Feb 27, 2018: FibroGen Announces Fourth Quarter and Full Year 2017 Financial Results 25
Nov 08, 2017: FibroGen Reports Third Quarter 2017 Financial Results 26
Aug 07, 2017: FibroGen Reports Second Quarter 2017 Financial Results 28
May 09, 2017: FibroGen Reports First Quarter 2017 Financial Results 29
Mar 01, 2017: FibroGen Reports Fiscal 2016 Financial Results 30
Corporate Communications 31
Sep 19, 2017: FibroGen Appoints Gerald Lema to Board of Directors 31
Product News 32
03/31/2017: FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS 32
Clinical Trials 33
Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease 33
Jan 30, 2017: FibroGens Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
FibroGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FibroGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FibroGen Inc, Deals By Therapy Area, 2012 to YTD 2018 8
FibroGen Inc, Medical Devices Deals, 2012 to YTD 2018 9
FibroGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 11
FibroGen Raises USD374.9 Million in Public Offering of Shares 12
FibroGen Raises USD120 Million in Public Offering of Shares 13
FibroGen Raises USD168 Million in IPO of Shares 15
FibroGen to Raise USD20 Million in Private Placement of Shares 17
FibroGen Inc, Key Competitors 19
FibroGen Inc, Key Employees 20
FibroGen Inc, Subsidiaries 21

List of Figures
FibroGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FibroGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
FibroGen Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[FibroGen Inc (FGEN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tiziana Life Sciences Plc (TILS):医療機器:M&Aディール及び事業提携情報
    Summary Tiziana Life Sciences Plc (Tiziana), formerly Alexander David Investments Plc, is a clinical stage biotechnology company that discovers and develops drugs to treat diseases in oncology and immunology. The company’s lead product candidate, TZLS-201, intended for the treatment of thymic carcin …
  • Blue Dolphin Energy Company (BDCO):石油・ガス:M&Aディール及び事業提携情報
    Summary Blue Dolphin Energy Company (Blue Dolphin) is an oil and gas company that refines and markets petroleum products. The company own and operate pipeline assets and have leasehold interests in oil and gas properties. It also acquires, develops and explores oil and gas properties. Blue Dolphin o …
  • MEDITE Cancer Diagnostics Inc (MDIT):企業の財務・戦略的SWOT分析
    MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Wahl Clipper Corporation:企業の戦略・SWOT・財務情報
    Wahl Clipper Corporation - Strategy, SWOT and Corporate Finance Report Summary Wahl Clipper Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Cre8tek Ltd (FGO):石油・ガス:M&Aディール及び事業提携情報
    Summary Cre8tek Ltd (Cre8tek), formerly Marion Energy Ltd, is an oil and gas exploration and production company. The company explores, acquires, develops, produces and markets oil and gas. It has core operations in Clear Creek field located in the Uinta Basin. Cre8tek also holds interest in the addi …
  • Mercury NZ Ltd:発電所・企業SWOT分析
    Mercury NZ Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • Federal Electricity & Water Authority:企業の戦略的SWOT分析
    Federal Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Global Alliance for TB Drug Development:製薬・医療:M&Aディール及び事業提携情報
    Summary Global Alliance for TB Drug Development (TB Alliance) is a non-profit organization that discovers and develops drugs to treat tuberculosis. The organization’s products include natural products, rifampin, pyrazinamide, isoniazid, macrokuds, ethambutol, and topoisomerase inhibitors. It offers …
  • Kerry Group plc:企業のM&A・事業提携・投資動向
    Kerry Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kerry Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Tulip Star Hotels Limited:企業の戦略・SWOT・財務分析
    Tulip Star Hotels Limited - Strategy, SWOT and Corporate Finance Report Summary Tulip Star Hotels Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Simcere Pharmaceutical Group-製薬・医療分野:企業M&A・提携分析
    Summary Simcere Pharmaceutical Group (Simcere) is a drug discovery company that manufactures and supplies branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas including anti-tumor, central nervous, anti-infection, cardiovascular, skeletal muscle, …
  • SQI Diagnostics Inc (SQD):企業の財務・戦略的SWOT分析
    Summary SQI Diagnostics Inc (SQI Diagnostics) is a diagnostic company that provides in vitro diagnostic and pharmaceutical research products. The company provides products such as sqidworks, sqidlite and sqid-X. Its sqidworks system is used in labs. SQI Diagnostic’s sqidlite is a practical benchtop …
  • Vedanta Resources Plc:企業のM&A・事業提携・投資動向
    Vedanta Resources Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vedanta Resources Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Eckert & Ziegler BEBIG SA (EZBG):企業の財務・戦略的SWOT分析
    Summary Eckert & Ziegler BEBIG SA (Eckert & Ziegler) a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG, is a medical device company that produces and distributes brachytherapy and radiotherapy products. The company offers products such as permanent prostate implants, HDR afterloaders, …
  • Eftec AG:企業の戦略的SWOT分析
    Eftec AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Consolidated Edison Company of New York, Inc.-エネルギー分野:企業M&A・提携分析
    Summary Consolidated Edison Company of New York, Inc. (CECONY), a subsidiary of Consolidated Edison, Inc. is an energy utility that generates, transmits and distributes electricity; supplies natural gas; and generates and supplies steam. The company provides electricity and related services in New Y …
  • University of Maryland Medical Center Corp:企業の戦略的SWOT分析
    University of Maryland Medical Center Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Tenaga Nasional Berhad:企業の戦略・SWOT・財務情報
    Tenaga Nasional Berhad - Strategy, SWOT and Corporate Finance Report Summary Tenaga Nasional Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Municipal Energy Agency of Nebraska:企業の戦略的SWOT分析
    Municipal Energy Agency of Nebraska - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Gamida Cell Ltd:企業のM&A・事業提携・投資動向
    Gamida Cell Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gamida Cell Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆